Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors

OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Strand, Vibeke, Reaney, Matthew, Chen, Chieh-I, Proudfoot, Clare W J, Guillonneau, Sophie, Bauer, Deborah, Mangan, Erin, Graham, Neil M H, van Hoogstraten, Hubert, Lin, Yong, Pacheco-Tena, César, Fleischmann, Roy
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5353328/
https://ncbi.nlm.nih.gov/pubmed/28326189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000416
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados